We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors

By LabMedica International staff writers
Posted on 09 May 2025

Current circulating cell-free DNA (cfDNA) assays are typically centralized, requiring specialized handling and transportation of samples. More...

Introducing a flexible, decentralized sequencing system at the point of care, which requires minimal technical oversight, could significantly improve turnaround times and expand patient access to genomic profiling. In a new study, researchers assessed the clinical feasibility of an automated, decentralized cfDNA next-generation sequencing (NGS) assay designed to identify actionable genetic alterations in advanced solid tumors.

The study, conducted by researchers at the Japanese Foundation for Cancer Research (JFCR, Tokyo, Japan), involved genomic profiling of plasma cfDNA from 298 patients with advanced solid tumors using an automated NGS assay. The team compared the tumor mutations detected in plasma cfDNA with those found in patient-matched tumor tissues, which were analyzed using an FDA-approved assay. They also examined clinical factors that could influence the sensitivity of ctDNA aberration (mut-ctDNA) detection. The researchers discovered that the sequencing success rates for cfDNA genomic profiling were significantly higher compared to archived tumor tissue (99% vs. 96%). The detection rates of mut-ctDNA ranged from 20% to 67% across various solid tumors, and targetable or resistance alterations were identified in 18% of patients.

The results, published in the journal Clinical Chemistry, also revealed that approximately 72% of patients showed consistent alterations between tissue and plasma samples. This level of concordance was linked to factors such as cancer type, tumor burden, and the metastatic location. Importantly, 63 plasma-only alterations were identified in 18% of patients, with these alterations being more common in patients who had previously received targeted treatments (24%) compared to those who had undergone chemotherapy (10%). The findings highlight the clinical viability of an automated, decentralized cfDNA genomic profiling method and emphasize the need to consider clinical factors when choosing between plasma- or tissue-based assays. This approach holds promise for improving patient access to timely genomic profiling and facilitating targeted therapy selection.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Autoimmune Disease Diagnostic
Chorus ds-DNA-G
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Early and effective screening for gestational diabetes mellitus is becoming increasingly important (Photo courtesy of Shutterstock)

First-Trimester Blood Test Accurately Predicts Gestational Diabetes

Gestational diabetes mellitus (GDM) affects many pregnancies and is typically detected midway through pregnancy, often too late to prevent complications. Women diagnosed late face increased risks such... Read more

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.